Find a clinical trial


If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 12345 Next »
Viewing Page 1 of 34 | Showing Results 1 - 5 of 167

CHECKMATE 817 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

A study to evaluate the safety of Nivolumab administered in combination with Ipilimumab in patients with advanced cancers. The initial cohort will...

Jason Lukas, M.D., Ph.D.
  • Providence Regional Cancer Partnership - Everett

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC. Stereotactic Ablative Radiotherapy has been shown in single...

Brian Louie, M.D.
  • Swedish Medical Center

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

1. Cohort 1(combination of niraparib and pembrolizumab): patients must have tumors with high PD-L1 expression (TPS ≥ 50%) per local assessment,...

Basir Haque, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

A Phase II Single-Arm Trial to Investigate Tepotinib in Stage IIIB/IV Adenocarcinoma of the Lung with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-Doublet-Containing Regimen

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer that carries a specific...

Howard (Jack) West, M.D.
  • Swedish Medical Center

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

General Inclusion Criteria (all dose escalation and expansion cohorts):• Have histologically or cytologically confirmed locally advanced (and not a...

Min Sung Park, M.D.
  • Swedish Medical Center
« Previous 12345 Next »
Viewing Page 1 of 34 | Showing Results 1 - 5 of 167